Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
The effect of tenofovir disoproxil fumarate (TDF) in combination with two boosted fosamprenavir regimens on amprenavir pharmacokinetic parameters was assessed in this prospective phase I crossover study with 30 healthy volunteers. The co-administration of TDF 300 mg once a day with fosamprenavir/ritonavir 1400/200 mg or 1400/100 mg once a day has no effect on the pharmacokinetics of amprenavir and results in non-significant increases of ritonavir pharmacokinetic parameters, suggesting that no dose modification is necessary when combining fosamprenavir/ritonavir with TDF.
Kurowski
Michael
M
Therapia GmbH, Berlin, Germany.
Walli
Ravi K
RK
Breske
Antje
A
Kruse
Guido
G
Stocker
Hartmut
H
Banik
Norbert
N
Richter
Heinz
H
Mazur
Dago
D
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D019540:Area Under Curve; D002219:Carbamates / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005663:Furans; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D018023:HIV Seronegativity; D006801:Humans; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage*; D063065:Organophosphonates / Q000008:administration & dosage*; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000068698:Tenofovir
D044966:Anti-Retroviral Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D000068698:Tenofovir; D000225:Adenine; D019438:Ritonavir; C426859:fosamprenavir